title: Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: could we stop the treatment? About four cases.
authors.affiliation: Department of Gastroenterology and Hepatology, Saint-André Hospital, University Hospital of Bordeaux and Victor Segalen University , Bordeaux , France.
authors.forename: Florian
authors.initials: F
authors.lastname: Poullenot
authors.forename: Paulette
authors.initials: P
authors.lastname: Bioulac-Sage
authors.forename: Hervé
authors.initials: H
authors.lastname: Laumonier
authors.forename: Jean
authors.initials: J
authors.lastname: Saric
authors.forename: Thibault
authors.initials: T
authors.lastname: Carteret
authors.forename: Jean-Frédéric
authors.initials: JF
authors.lastname: Blanc
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000601:surgery; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D011859:Radiography; D000077157:Sorafenib; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib